News

The EORTC-PAMM Meeting was successfully held on 21-22 April 2021, and the journal Cancer Drug Resistance supported two awards for the best presentation on each day of the meeting.

We would like to sincerely thank each and every reviewer who dedicated his or her time to reviewing manuscripts for Cancer Drug Resistance (CDR) in 2020. In the review process, at least two experts contribute comments about each paper published in CDR.

On 4th March, the Editorial Office received the pleasant news from Scopus Title Evaluation Support that Cancer Drug Resistance (CDR, ISSN:2578-532X (Online)) had been indexed in Scopus databse after rigorously evaluated by the Content Selection & Advisory Board (CSAB).

To provide young scholars with an active academic exchange platform for exchanging ideas with each other and with influential experts in cancer drug resistance, and cultivate candidates for Editorial Board of Cancer Drug Resistance (CDR), the Editorial Office plans to recruit junior Editorial Board members worldwide from now on.

As of August 28, 2020, the three-month work of expanding the Editorial Board of Cancer Drug Resistance (CDR) has come to a successful conclusion. A total of 30 scientists with significant international influence in the field of cancer drug resistance joined the Editor Board, with the ambition to help create a better future for CDR.

Rigorous and impartial peer-review process is very essential for success of a journal. We would like to sincerely thank each and every reviewer who dedicated his or her time and expertise to reviewing manuscripts for Cancer drug resistance (CDR) in 2019.

New Year's Blessings from Editorial Office of Cancer Drug Resistance

We would like to tell you that Cancer Drug Resistance (CDR), together with two sister journals Journal of Cancer Metastasis and Treatment (JCMT) and Hepatoma Research (HR), will attend AACR 2020 Annual Meeting as the leading journal! Welcome to visit us at Booth #1410!

We are pleased to announce that the journal of Cancer Drug Resistance is Now a member of the Committee on Publication Ethics (COPE). Please see details at: https://publicationethics.org/members/cancer-drug-resistance

Since the first issue of Cancer drug resistance (CDR) officially published on March 19, 2018, more and more scholars pay attention to this journal and inspired by the journal's achievement throughout the year. In 2018, CDR has totally published 20 papers of which have been cited 14 times within this year.

We would like to sincerely thank each and every reviewer who dedicated his or her time and expertise to reviewing manuscripts for Cancer drug resistance (CDR). In the review process, at least two experts contribute comment about each paper published in CDR, without their help, we would not be as fast-growing as it is today. Thus, the Journal of Cancer Drug Resistance acknowledge with particular gratitude the following reviewers who give freely of their support during the period March 2018-December 2018.

We now offer an article collection of Cancer drug resistance (CDR) Speical Issues to our authors, which are freely available for download on our website. If you are the Guest Editor of any of these Special Issues, please feel free to contact us for the printed version of the Ebooks. Your kind promotion of this collection through either conferences or other means would be highly appreciated.

For the future development, Cancer Drug Resistance (Cancer Drug Resist) held its first strategic planning symposium on August 26, 2016 and all team members joined it. This meeting aimed to discuss the planning and development strategies by inviting Prof. Peters. According to the orientation of the journal, Prof. Peters said that current academic journals on cancer drugs cover many areas on drug metabolism, pharmacology, drug actions, drug development, biomarkers and many more items, but a specific journal on cancer drug resistance does not exist, except for a general review journal Drug Resistance Update. Therefore, he expects that the planned journal has a great development prospect.